- Home
- INKT vs CTSO Comparison
INKT vs CTSO Comparison
Compare INKT & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- CTSO
- Stock Information
- Founded
- INKT 2017
- CTSO 1997
- Country
- INKT United States
- CTSO United States
- Employees
- INKT N/A
- CTSO N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- CTSO Medical/Dental Instruments
- Sector
- INKT Health Care
- CTSO Health Care
- Exchange
- INKT Nasdaq
- CTSO Nasdaq
- Market Cap
- INKT 69.2M
- CTSO 61.7M
- IPO Year
- INKT 2021
- CTSO N/A
- Fundamental
- Price
- INKT $14.55
- CTSO $0.92
- Analyst Decision
- INKT Buy
- CTSO Buy
- Analyst Count
- INKT 3
- CTSO 2
- Target Price
- INKT $37.50
- CTSO $5.50
- AVG Volume (30 Days)
- INKT 45.1K
- CTSO 130.7K
- Earning Date
- INKT 11-13-2025
- CTSO 11-06-2025
- Dividend Yield
- INKT N/A
- CTSO N/A
- EPS Growth
- INKT N/A
- CTSO N/A
- EPS
- INKT N/A
- CTSO N/A
- Revenue
- INKT N/A
- CTSO $36,107,520.00
- Revenue This Year
- INKT N/A
- CTSO $11.93
- Revenue Next Year
- INKT N/A
- CTSO $21.22
- P/E Ratio
- INKT N/A
- CTSO N/A
- Revenue Growth
- INKT N/A
- CTSO 20.18
- 52 Week Low
- INKT $4.56
- CTSO $0.71
- 52 Week High
- INKT $76.00
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- INKT 48.69
- CTSO 45.27
- Support Level
- INKT $13.11
- CTSO $0.87
- Resistance Level
- INKT $15.09
- CTSO $0.95
- Average True Range (ATR)
- INKT 1.03
- CTSO 0.05
- MACD
- INKT 0.00
- CTSO -0.00
- Stochastic Oscillator
- INKT 46.57
- CTSO 33.85
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.